Adaptimmune Therapeutics (ADAP) Reports In-Line Q3 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/18/2026
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Oil touches $110 a barrel for first time since May on Middle East, Russia supply fears
- Stay risk-off as higher real yields and AI volatility threaten stocks: BofA
- Apple’s first foldable iPhone sells out within minutes as preorders begin
- CoreWeave bond rout tests market's math on AI buildout
Tweet
Share
E-mailGet Alerts ADAP Hot Sheet
Join SI Premium – FREE
Adaptimmune Therapeutics (NASDAQ: ADAP) reported Q3 EPS of ($0.01), in-line with the analyst estimate of ($0.01). Revenue for the quarter came in at $40.9 million versus the consensus estimate of $18.57 million.
For earnings history and earnings-related data on Adaptimmune Therapeutics (ADAP) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Punjab National Bank (PNB:IN) PT Raised to INR130 at Kotak
- Axis Bank Ltd. (AXSB:IN) PT Raised to INR1,620 at JPMorgan
- Metro Brands Ltd (METROBRA:IN) PT Lowered to INR950 at Kotak
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
